Use of μ1-opioid receptor agonist tafalgin in integrative therapy of chronic pain syndrome in progressive multiple myeloma. Clinical observation
Yu. E. Ryabukhina,
P. A. Zeynalova,
O. L. Timofeeva,
F. M. Abbasbeyli,
V. E. Gruzdev,
A. O. Akhov,
A. G. Zhukov,
T. T. Valiev https://doi.org/10.17650/2782-3202-2023-3-2-27-34
Abstract
Chronic pain syndrome developing in patients with oncological diseases significantly decreases their quality of life which makes effective integrative analgetic therapy a pressing issue. Currently, drugs of various pharmaceutical groups are used for pain management and administered subsequentially in accordance with the pain intensity visual analogue scale. For moderate and severe pain syndrome, opioid analgesics are used which have side effects limiting their use in some cases. Trials showed that new highly specific μ1-opioid receptor agonist tafalgin is characterized by high bioavailability, fast absorption, biotransformation, absence of accumulation which makes its safety profile favorable. Pronounced analgesic effect of tafalgin, as well as ease of administration and absence of significant adverse events, allow to significantly improve the quality of life of patients with chronic pain syndrome.
About the Authors
Yu. E. Ryabukhina
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
Yulia Evgenyevna Ryabukhina
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
P. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
111 1stUspenskoe Shosse, Lapino, Moscow region 143081
Bld. 2, 8 Trubetskaya St., Moscow 119991
O. L. Timofeeva
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
F. M. Abbasbeyli
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
V. E. Gruzdev
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
A. O. Akhov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
A. G. Zhukov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
T. T. Valiev
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Bld. 2, 8 Trubetskaya St., Moscow 119991
References
1. Danilov A.A. Neuropathic pain. Klinicheskaya gerontologiya = Clinical gerontology 2007;2:27–36. (In Russ.).
2. Stamo А.P., Grigoryeva V.N. Clinical characteristics of pain syndrome in patients with multiple myeloma. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2016;116(10):11–15. (In Russ.). DOI: 10.17116/jnevro201611610111-15
3. Vital A. Paraproteinemic neuropathies. Brain Pathol 2001;11(4):399–407. DOI: 10.1111/j.1750-3639.2001.tb00407.x
4. Sobol U., Stiff P. Neurologic aspects of plasma cell disorders. Handb Clin Neurol 2014;120:1083–99. DOI: 10.1016/B978-0-7020-4087-0.00073-5
5. Niscola P., Perroti A.P., del Poeta G. et al. Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures. Herpes 2007;14(2):45–7.
6. Boonyapakorn T., Schirmer I., Reichart P.A. et al. Bisphosphonateinduced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44(9):857–69. DOI: 10.1016/j.oraloncology.2007.11.012
7. Kogonia L.M., Novikov G.A., Orlova R.V. et al. Practical recommendations for the treatment of chronic pain syndrome in adult cancer patients. Zlokachestvenniye opukholy. Prakticheskiye rekomendatsii RUSSCO = Malignant tumors. Practical recommendations of RUSSCO 2022;12(3s2): 182–202. (In Russ.). DOI: 10.18027/2224-5057-2022-12-3s2-182-202 8. Niscola P., Scaramucci L., Romani C. et al. Pain management in multiple myeloma. Expert Rev Anticancer Ther 2010;10(3):415–25. DOI: 10.1586/era.10.5
8. Grond S., Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43(13):879–923. DOI: 10.2165/00003088-200443130–00004
9. Coluzzi F., Rolke R., Mercadante S. Pain management in patients with multiple myeloma: an update. Cancers (Basel) 2019;11(12):2037. DOI: 10.3390/cancers11122037
10. Kosorukov V.S., Abuzarova G.R., Zakharochkina E.R. et al. Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials. Opukholi golovy i shei = Head and Neck Tumors 2022;12(2):89–107. (In Russ.). DOI: 10.1765/ 222-1468-2022-12-2-89-107
11. Abuzarova G.R., Sarmanayeva R.R., Alekseeva G.S., Brazhnicova Y.V. A clinical case of the use of a new selective μ1-opioid analgesic Tafalgin in the treatment of chronic cancer pain. Sovremennaya onkologiya = Journal of Modern Oncology 2022;24(3):313–8. (In Russ.). DOI: 10.26442/18151434.2022.3.201913
12. Abuzarova G.R., Kosorukov V.S., Gamzeleva O.Yu. et al. The efficacy and safety of Tafalgin in patients with cancer pain. Results of an openlabel comparative multicenter randomized clinical trial. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2022;11(5):38–48. (In Russ.). DOI: 10.17116/onkolog20221105138
Review
For citations:
Ryabukhina Yu.E., Zeynalova P.A., Timofeeva O.L., Abbasbeyli F.M., Gruzdev V.E., Akhov A.O., Zhukov A.G., Valiev T.T. Use of μ1-opioid receptor agonist tafalgin in integrative therapy of chronic pain syndrome in progressive multiple myeloma. Clinical observation. MD-Onco. 2023;3(2):27-34. (In Russ.) https://doi.org/10.17650/2782-3202-2023-3-2-27-34
Views:
332
Email this article 